Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.
Shruti ChandraCristina ArpaDeepthy MenonHagar KhalidRobin HamiltonLuke NicholsonBishwanath PalSandro FasoloPhilip HykinPearse A KeaneSobha SivaprasadPublished in: Eye (London, England) (2020)
Regular monitoring and anti-VEGF treatment over 10 years reduce the risk of visual loss of 15 letters or more in patients with neovascular AMD. The most common cause of substantial visual decline was macular atrophy.